FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support ...

The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...

A new study shows that oxytocin nasal spray helps mothers with postpartum depression interact more positively with their babies.

New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

People with hay fever could one day benefit from a first-of-its-kind “molecular shield” that blocks pollen from entering the ...

A “MOLECULAR shield” placed in the nose could prevent hay fever symptoms, a study suggests. Scientists have engineered an ...

New Opportunities will be offering a free “Be Prepared” presentation to assist in identifying and how to respond to an opioid overdose. On July 18 at the Audubon Rec Center Community Room, New Opportu ...

New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL an ...

New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Phar ...

Vaccine experts have developed an antibody that, when applied to the nose, intercepts allergens before they can trigger a ...

Milestone Pharmaceuticals (MIST) stock falls amid a capital raise as FDA agrees to review its resubmitted NDA for heart therapy Cardamyst. Read more here.